3 Stocks I Saw on T...
Health Care: Drugs
Cytori Therapeutics Inc. (CYTX: NASDAQ)
$2.13 0.05 | 2.40%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.83 | 0.58 | 0.98 |
| Price to Sales (TTM) | 17.77 | 4.62 | 1.42 |
| Price to Book (MRQ) | 17.82 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 43.72 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -4.30 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -3.70 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -42.90 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -24.90 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 7.65 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -22.57 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.30 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 3.70 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 2.88 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 3.59 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 67.10 | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 89.80 | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -312.34 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -4.32 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -60.50 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -74.80 | 2.20 | 2.50 |
| Return on Investment (TTM) | -111.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -256.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 53,672.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -232,070.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 4.30 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | 0.70 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.10 | 0.40 | 0.40 |
Portfolios with CYTX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor6 Drug Stocks Unworthy of B...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Stocks Under-$10 Setting ...
- ContributorBreakout Stocks Of The Week...
- ContributorStem Cell Stocks
- Usermurphman Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
Latest CYTX Headlines from TheStreet
- 8 Stocks Under $10 Soaring Higher 05.10.12 | 01:05 pm
- Tuesday's Top 10 Articles, Videos on TheStreet 02.07.12 | 01:02 pm
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 8 Stocks Under $10 Ripping Higher 01.26.12 | 02:01 pm
- Cytori Therapeutics Inc. (CYTX): Today's Featured Drugs Loser 09.29.11 | 04:09 pm
- Biotech Stock Mailbag: Mela Sciences 09.09.11 | 06:09 am
- Biotech Stock Mailbag: Cytori Therapeutics 05.20.11 | 07:05 am
- Cytori Therapeutics Inc. Stock Downgraded (CYTX) 05.10.11 | 06:05 am
- Cytori Stock Hits New 52-Week High (CYTX) 04.04.11 | 10:04 am
- Cytori Therapeutics Inc. Stock Upgraded (CYTX) 03.24.11 | 06:03 pm
Press Releases for CYTX
- Cytori Therapeutics Announces Independent Clinical Study Results In Breast Reconstruction Presented At The Association Of Breast Surgery Conference - Business Wire 05.17.11 | 05:05 am
- Catholic Healthcare West President/CEO Lloyd H. Dean To Join Cytori Therapeutics’ Board Of Directors - Business Wire 11.03.10 | 07:11 am
- Cytori Announces Exercise In Full Of Overallotment Option And Closing Of Public Offering Of Common Stock; Raises $19.3 Million In Net Proceeds - Business Wire 10.13.10 | 09:10 am
- Cytori Therapeutics Prices Public Offering Of Common Stock - Business Wire 10.08.10 | 08:10 am
- Cytori Therapeutics Proposes Common Stock Public Offering - Business Wire 10.07.10 | 04:10 pm
- Adipose-Derived Stem & Regenerative Cells Reduce Mortality, Improve Renal Function In Preclinical Acute Kidney Injury Study Data Published Today - Business Wire 10.05.10 | 08:10 am
- Cytori Extends Distribution Agreement With GE Healthcare; Key Focus On Research Market - Business Wire 09.16.10 | 07:09 am
- Cytori Therapeutics Announces Fall 2010 U.S. Conference Schedule - Business Wire 09.13.10 | 07:09 am
- Cytori Issued Celution® System Patent For Orthopedic & Spinal Disc Diseases - Business Wire 08.12.10 | 07:08 am
- Cytori’s PureGraft™ System Receives European Approval For Fat Grafting Procedures - Business Wire 07.29.10 | 08:07 am
Partner Headlines for CYTX
- Cytori Is A Compelling Short Sale Opportunity - Seeking Alpha 03.19.12 | 09:03 am
- Earnings Report Card, Regenerative Medicine Universe Edition - Seeking Alpha 08.11.11 | 09:08 am
- Analyst Interview - International Stem Cell - Analyst Blog - Zacks 07.27.11 | 06:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Cytori Therapeutics: Sales Miss? Yes. Bad Quarter? No - Seeking Alpha 05.06.11 | 03:05 pm
- Some Hidden Gem Stocks That May Have High Returns! - AOL 04.05.11 | 07:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- 9 Cheap Stocks Under $10 Making New Price Highs - Seeking Alpha 03.25.11 | 08:03 am
- Options Brief: Cytori Therapeutics (CYTX) - Benzinga 03.17.11 | 01:03 pm
- UPDATE 1-Cytori, Astellas Pharma sign $10 mln equity deal - Reuters 12.07.10 | 07:12 am
